Johnson & Johnson - 63 Year Stock Split History | JNJ

Stock split history for Johnson & Johnson since 1962. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Johnson & Johnson Annual Stock Splits
Johnson & Johnson Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $367.985B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $676.408B 51.87
AbbVie (ABBV) United States $323.711B 17.84
Novo Nordisk (NVO) Denmark $302.235B 19.93
Roche Holding AG (RHHBY) Switzerland $253.013B 0.00
Novartis AG (NVS) Switzerland $238.176B 13.60
Merck (MRK) United States $194.806B 9.96
Pfizer (PFE) United States $132.583B 7.26
Sanofi (SNY) France $127.479B 12.56
Bayer (BAYRY) Germany $27.508B 5.60
Innoviva (INVA) United States $1.191B 12.48